<div class="infobox infobox-gene">
<h3>SMO (Smoothened)</h3>
<table>
<tr><td><strong>Full Name</strong></td><td>Smoothened, Frizzled Class Receptor</td></tr>
<tr><td><strong>Gene Symbol</strong></td><td>SMO</td></tr> [@bambakidis2012]
<tr><td><strong>Chromosomal Location</strong></td><td>7q32.1</td></tr> [@yue2010]
<tr><td><strong>NCBI Gene ID</strong></td><td>[6608](https://www.ncbi.nlm.nih.gov/gene/6608)</td></tr> [@petrova2020]
<tr><td><strong>OMIM</strong></td><td>[601500](https://omim.org/entry/601500)</td></tr> [@yauch2009]
<tr><td><strong>Ensembl</strong></td><td>[ENSG00000128602](https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000128602)</td></tr> [@xie1998]
<tr><td><strong>UniProt (Protein)</strong></td><td>[Q99835 (Smoothened homolog)](https://www.uniprot.org/uniprot/Q99835)</td></tr> [@varjosalo2008]
<tr><td><strong>Associated Diseases</strong></td><td>[Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), [ALS](/diseases/amyotrophic-lateral-sclerosis), Medulloblastoma, Basal Cell Carcinoma</td></tr>
</table>
</div>
<div class="infobox infobox-gene">
<h3>SMO (Smoothened)</h3>
<table>
<tr><td><strong>Full Name</strong></td><td>Smoothened, Frizzled Class Receptor</td></tr>
<tr><td><strong>Gene Symbol</strong></td><td>SMO</td></tr> [@bambakidis2012]
<tr><td><strong>Chromosomal Location</strong></td><td>7q32.1</td></tr> [@yue2010]
<tr><td><strong>NCBI Gene ID</strong></td><td>[6608](https://www.ncbi.nlm.nih.gov/gene/6608)</td></tr> [@petrova2020]
<tr><td><strong>OMIM</strong></td><td>[601500](https://omim.org/entry/601500)</td></tr> [@yauch2009]
<tr><td><strong>Ensembl</strong></td><td>[ENSG00000128602](https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000128602)</td></tr> [@xie1998]
<tr><td><strong>UniProt (Protein)</strong></td><td>[Q99835 (Smoothened homolog)](https://www.uniprot.org/uniprot/Q99835)</td></tr> [@varjosalo2008]
<tr><td><strong>Associated Diseases</strong></td><td>[Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), [ALS](/diseases/amyotrophic-lateral-sclerosis), Medulloblastoma, Basal Cell Carcinoma</td></tr>
</table>
</div>
SMO (Smoothened, Frizzled Class Receptor) encodes a 793 amino acid class F G protein-coupled receptor (GPCR) that serves as the essential signal transducer of the [Hedgehog (Hh) signaling pathway](/mechanisms/hedgehog-pathway). In the canonical pathway, binding of Hedgehog ligands ([SHH](/genes/shh), IHH, DHH) to the receptor [Patched1 (PTCH1)](/genes/ptch1) relieves PTCH1-mediated inhibition of SMO, allowing SMO to activate downstream [GLI](/genes/gli1) transcription factors. SMO is a master regulator of neural development, adult neurogenesis, and neuroprotection, and its dysregulation has been implicated in neurodegenerative diseases, cerebellar pathology, and brain tumors.
SMO spans approximately 25 kb on chromosome 7q32.1 and contains 12 exons encoding a 793 amino acid seven-transmembrane protein. The promoter region contains binding sites for Sp1, NF-Y, and AP-2 transcription factors. Alternative splicing generates minor transcript variants, though the canonical full-length isoform predominates in neural tissue.
In the developing brain, SMO is ubiquitously expressed in neural progenitor cells of the ventricular zone, the external granular layer of the cerebellum, and the subventricular zone (SVZ). In the adult brain, expression is maintained in neurogenic niches — the SVZ and the subgranular zone (SGZ) of the hippocampal dentate gyrus — as well as in [astrocytes](/cell-types/astrocytes), [Bergmann glia](/cell-types/bergmann-glia), and cerebellar [Purkinje cells](/cell-types/purkinje-cells). The [Allen Brain Atlas](https://human.brain-map.org/) shows moderate expression across cortical regions with enrichment in the cerebellum, [hippocampus](/brain-regions/hippocampus), and hypothalamus.
Smoothened is a seven-transmembrane receptor belonging to the Frizzled class (class F) of GPCRs. The protein contains an extracellular cysteine-rich domain (CRD) that binds cholesterol and oxysterols, a seven-transmembrane core domain with a deep binding pocket for small-molecule modulators, and a long intracellular C-terminal tail that recruits downstream effectors.
In the absence of Hedgehog ligand, [PTCH1](/genes/ptch1) localizes to the primary cilium and suppresses SMO by depleting accessible cholesterol from the ciliary membrane. SMO remains in intracellular vesicles, and the [GLI](/genes/gli1) transcription factors are processed into repressor forms (GLI3R) by the [SUFU](/genes/sufu)–[KIF7](/genes/kif7) complex and [protein kinase A (PKA)](/genes/prkaca). When SHH binds PTCH1, PTCH1 exits the cilium, cholesterol accumulates, and SMO undergoes a conformational change enabling its translocation to the ciliary tip. Active ciliary SMO recruits and activates full-length GLI2/3 activators (GLI2A/GLI3A), which translocate to the nucleus and drive transcription of Hh target genes including [GLI1](/genes/gli1), PTCH1, [CCND1](/genes/ccnd1), and [BCL2](/genes/bcl2).
Beyond the canonical GLI-dependent pathway, SMO activates several non-canonical effectors relevant to neurodegeneration:
SMO activity is tightly regulated by its subcellular localization. Phosphorylation of the SMO C-terminal tail by [CK1](/genes/csnk1a1) and [GRK2](/genes/grk2) promotes ciliary accumulation and full activation. Ubiquitination by the HECT-domain E3 ligases HERC4 and SMURF1/2 targets SMO for lysosomal degradation. Cholesterol and oxysterols (particularly 20(S)-hydroxycholesterol) serve as endogenous SMO agonists by binding the CRD, while the plant alkaloid cyclopamine and clinically approved drugs vismodegib and sonidegib are SMO antagonists that bind the transmembrane domain.
SMO-mediated Hedgehog signaling is indispensable for multiple aspects of CNS development:
Hedgehog signaling through SMO is progressively impaired in [AD](/diseases/alzheimers-disease). [Amyloid-beta (Aβ)](/proteins/amyloid-beta) oligomers directly inhibit SMO ciliary trafficking in hippocampal neurons, reducing GLI1 target gene expression and compromising neuroprotective programs. Postmortem AD brains show decreased SHH, SMO, and GLI1 expression in the hippocampus and [entorhinal cortex](/brain-regions/entorhinal-cortex). Pharmacological activation of SMO with the agonist SAG (Smoothened AGonist) rescues Aβ-induced neurotoxicity in primary hippocampal cultures and improves spatial memory in [APP](/entities/app-protein)/PS1 transgenic mice. SMO agonism upregulates [BDNF](/genes/bdnf), reduces [tau](/genes/mapt) hyperphosphorylation via [GSK-3β](/genes/gsk3b) inhibition, and promotes adult hippocampal neurogenesis — suggesting that restoring Hedgehog signaling may counteract multiple AD pathomechanisms simultaneously.
SMO-dependent Hedgehog signaling is critical for the development and maintenance of midbrain [dopaminergic (DA) neurons](/cell-types/dopaminergic-neurons). SHH is a survival factor for DA neurons, and conditional SMO deletion in the adult midbrain leads to progressive DA neuron loss reminiscent of [PD](/diseases/parkinsons-disease). In PD models, [α-synuclein](/entities/snca) aggregation impairs primary cilium structure, disrupting SMO ciliary trafficking and downstream GLI activation. The SMO agonist purmorphamine protects DA neurons against 6-OHDA and MPTP toxicity in both in vitro and in vivo models. Additionally, SMO signaling promotes the conversion of reactive [astrocytes](/cell-types/astrocytes) into functional DA neurons via [Nurr1](/genes/nr4a2)/[Pitx3](/genes/pitx3) upregulation — a finding with implications for cell replacement strategies in PD.
Hedgehog signaling is dysregulated in the spinal cord of [ALS](/diseases/amyotrophic-lateral-sclerosis) patients and SOD1-G93A mice. SMO expression is reduced in motor neurons and surrounding [astrocytes](/entities/astrocytes) in the ventral horn. SHH supplementation or SMO agonist treatment (SAG) extends survival in SOD1 mice, associated with preserved motor neuron morphology, reduced [GFAP](/genes/gfap)-positive astrogliosis, and decreased [NF-κB](/mechanisms/nf-kb-pathway)-driven neuroinflammation. SMO signaling in astrocytes promotes their conversion from the neurotoxic A1 to the neuroprotective A2 phenotype, reducing release of pro-inflammatory cytokines ([TNF-α](/genes/tnf), [IL-1β](/genes/il1b), [C3](/genes/c3)).
Gain-of-function mutations in SMO (e.g., W535L, the "SmoM2" mutation) cause constitutive ligand-independent activation and are found in approximately 10% of SHH-subgroup medulloblastomas. These mutations render SMO insensitive to PTCH1 inhibition and drive uncontrolled proliferation of cerebellar GNPs. FDA-approved SMO antagonists vismodegib and sonidegib are used clinically for basal cell carcinoma and are in trials for SHH-medulloblastoma.
| Variant | Type | Association | Reference |
|---------|------|-------------|-----------|
| rs2228617 (V329I) | Missense | Altered SMO activity, medulloblastoma risk | [Reifenberger et al., 1998](https://pubmed.ncbi.nlm.nih.gov/9823340/) |
| W535L (SmoM2) | Somatic gain-of-function | Constitutive activation, medulloblastoma | [Xie et al., 1998](https://doi.org/10.1038/30515) |
| rs1417354981 | Intronic | Cerebellar volume variation | [Genome-wide studies](https://www.ebi.ac.uk/gwas/) |
| D473H | Drug resistance | Vismodegib resistance in BCC | [Yauch et al., 2009](https://doi.org/10.1126/science.1171589) |
| Brain Region | Expression Level | Cell Types |
|---|---|---|
| Cerebellum | High | Purkinje cells, Bergmann glia, GNPs |
| Hippocampus (SGZ) | Moderate-High | Neural stem cells, granule neurons |
| SVZ | High | Neural stem cells, transit-amplifying progenitors |
| Cerebral [cortex](/brain-regions/cortex) | Moderate | Pyramidal neurons, astrocytes |
| Ventral midbrain | Moderate-High | Dopaminergic neurons, astrocytes |
| Spinal cord (ventral horn) | Moderate | Motor neurons, astrocytes |
The following diagram shows the key molecular relationships involving SMO — Smoothened, Frizzled Class Receptor discovered through SciDEX knowledge graph analysis: